![John Mulligan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Mulligan is the founder and CEO of Good Therapeutics, Inc. which was founded in 2016.
He is also the founder of Bonum Therapeutics, Inc.
| Unternehmen | Position | Beginn |
|---|---|---|
Good Therapeutics, Inc.
 Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops bio-therapeutics and self-regulating drugs | Gründer | 01.01.2016 |
Bonum Therapeutics, Inc.
 Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antibody-controlled cytokine based therapeutics designed to enhance the anti-tumor immune response | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 2 |
|---|---|
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops bio-therapeutics and self-regulating drugs | Health Technology |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antibody-controlled cytokine based therapeutics designed to enhance the anti-tumor immune response | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
